Medicare's Bundled Payments for Care Improvement (BPCI) initiative for lower extremity joint replacement (LEJR) surgery has been associated with a reduction in episode spending and stable-to-improved quality. However, BPCI may create unintended effects by prompting participating hospitals to increase the overall volume of episodes paid for by Medicare, which could potentially eliminate program-related savings or prompt them to shift case mix to lower-risk patients.
However, existing evaluations have not examined changes in overall episode volume and have included limited analysis of changes in case mix. Consequently, 2 major policy concerns remain: Are bundled payments associated with increases in the overall volume of episodes paid for by Medicare, and are they associated with changes in case mix? Experts have expressed concern that Medicare savings could decrease or be eliminated if bundled payments prompt hospitals to perform more LEJR episodes than they otherwise would under fee-for-service payment plans. 7, 8 Critics have also noted that voluntary bundled payments may prompt hospitals to cherry pick lower-risk patients based on socioeconomic, racial, or clinical factors to improve quality and cost performance.
9-11
Empirical evidence for both would be highly relevant as policy makers continue promoting voluntary bundled payments via the forthcoming BPCI Advanced program, 12 which extends major elements of the BPCI Model 2 and includes LEJR. Therefore, this study analyzed Medicare data using a difference-in-differences approach to evaluate whether participation in Model 2 for LEJR was associated with changes in procedural volume or case mix.
Methods
This study was approved by the University of Pennsylvania Institutional Review Board with a waiver of informed consent because contacting study participants was not feasible.
Data and Study Period
We used 100% Medicare provider analysis and review files from 2011 and 2015, which contain encounter-level information about inpatient hospitalizations, and the BPCI analytic file to identify hospitals participating in BPCI Model 2. 1 All hospitalizations were examined to identify procedures as complicated, defined as procedures designated under Medicare severitydiagnosis related group (MS-DRG) 469 as having major complications or comorbidities or as uncomplicated, procedures designated under MS-DRG 470 and without major complications or comorbidities. Data from the American Hospital Association (AHA), Hospital Compare, and Medicare's provider of service, beneficiary summary, and accountable care organization (ACO) provider-level research-identifiable files were used to obtain market and hospital characteristics. [13] [14] [15] [16] Hospital safety net status was determined by the amount of the disproportionate share hospital payments recorded in the CMS Impact file. Two study periods were defined: the pre-BPCI period, which spanned the first quarter of 2011 through the third quarter of 2013 (January 2011-September 2013) and the BPCI period, which spanned the fourth quarter of 2013 through the fourth quarter of 2015 (October 2013 -December 2015 .
Unit of Analysis
Analysis of hospital LEJR volume could have been confounded had clinicians and hospitals directed patients to bundledpayment hospitals and away from nonbundled-payment hospitals, driving market share changes rather than changes in the overall number of episodes paid for by Medicare. 11 Therefore, the primary analysis evaluated quarterly LEJR volume at the level of health care markets, defined by hospital referral regions. Hospital-level sensitivity analyses were conducted to corroborate findings from earlier work. 17 Conversely, the association between BPCI participation and case mix was analyzed at the hospital rather than market level because lower-risk patients may be preferentially directed to BPCI-participant hospitals.
BPCI Participation as Exposure Measure
A dichotomous measure of whether each market had any BPCI-participant hospitals at any point was used for descriptive purposes. All other analyses used a lagged continuous quarterly measure of LEJR market share for BPCI-participant hospitals. To construct this measure, the first step included measuring LEJR market shares at each hospital before the BPCI program launched, to avoid circularity that would result from using LEJR market-quarter volume as both a dependent variable and as a component of the exposure variable. Second, in each quarter in the BPCI period, the pre-BPCI LEJR market shares for participant hospitals were summed in that market quarter, and this market-level value for BPCI participation was assigned as the quarterly exposure in BPCI markets ( Figure 1 ; and eFigure 1 in Supplement 1). This market-quarter value was set to 0 in the pre-BPCI period and updated in each quarter in
Key Points
Question Is hospital participation in Medicare's Bundled Payments for Care Improvement (BPCI) program for lower extremity joint replacement (LEJR) associated with changes in overall procedural volume, case mix, or both?
Findings In this observational study involving 1 717 243 Medicare beneficiaries who underwent LEJR, hospital participation in the BPCI initiative was not associated with changes in overall market-level LEJR volume (adjusted difference-in-differences estimate, 0.32%) and largely was not associated with changes in hospital case mix, with only 1 of 20 case-mix characteristics associated with a lower likelihood of undergoing LEJR at a BPCI-participating hospital.
Meaning The lack of associations between Bundled Payments for Care Improvement program participation and changes in volume or the majority of patient case-mix factors may provide reassurance about 2 potential unintended effects of voluntary bundled payments for lower extremity joint replacement.
the BPCI period so that it increased as more hospitals joined BPCI within a market. All hospital-level analyses used a dichotomous time-varying indicator of BPCI participation by quarter.
Outcome Measures
Market Volume was defined as the number of LEJR hospitalizations within each market per quarter, stratified by uncomplicated or complicated LEJR. Changes in case mix were evaluated through a series of hospital-level measures based on patient characteristics. Beneficiary-level case-mix outcomes were categorized by demographics, indicators of socioeconomic status, clinical indicators, and health care facility use in the prior 12 months. Demographic variables included advanced age (≥85 years), dichotomous indicators for black race (designated using Medicare claims data definitions, with an indicator for black race vs other races because of existing disparities in access to LEJR among patients with black race specifically), and sex. Indicators of socioeconomic status included dichotomous variables for dual eligibility for Medicare and Medicaid, and low education and income levels in area of residence (bottom quartile of zip codes nationally). Clinical indicators included dichotomous clinical variables representing presence of high complexity (top 20% of mean Elixhauser comorbidity index, 18 calculated using conditions present in the year preceding LEJR hospitalization), obesity, diabetes, diabetes with complications, coronary heart disease, congestive heart failure, alcohol use, depression, psychoses, frailty, 19,20 and 2 or more Elixhauser comorbidities.
Health care facility use in the prior 12 months before LEJR hospitalization included acute care hospital, skilled nursing facility, or inpatient rehabilitation facility.
Covariates Market-and hospital-level analyses incorporated covariates that reflected market-level characteristics of patients (age, sex, race), hospitals (number of beds), and market structure (hospital and skilled nursing facility concentration, ACO penetration, Medicare Advantage penetration, and presence of physician group practice). Hospital and skilled nursing facility market concentration was determined via the HerfindahlHirschman index (HHI).
Statistical Analysis
We described characteristics for BPCI and non-BPCI markets and hospitals, as well as quarterly trends in BPCI enrollment, number of markets with BPCI-participant hospitals, and market level BPCI participation. To evaluate the association between BPCI participation and changes in LEJR volume, a difference-in-differences method 21 was used to estimate differential changes in mean market volume, as well as mean market volume per 1000 beneficiaries to adjust for differences in market size, for BPCI and non-BPCI markets in both periods. In adjusted analysis with the covariates above, unconditional negative binomial models adjusted for market size (using the number of beneficiaries per market per quarter) were used for market volume (to avoid bias from large numbers of fixed effects in nonlinear regression). Within-market changes for BPCI markets before and after BPCI participation to changes in non-BPCI markets were compared using market and quarter fixed effects. Changes in market volume were plotted using predicted quarterly values for non-BPCI markets, BPCI markets, and the counterfactual of BPCI markets without any volume changes due to participation (eMethods 1 in Supplement 1).
In sensitivity analyses, negative binominal models containing hospital and quarter fixed effects along with the covariates in market-level analyses were used to evaluate the association of hospital BPCI participation with hospital-level LEJR volume and market share. We compared participant hospitals (1) with all nonparticipant hospitals in non-BPCI markets and (2) with a propensity-matched set of nonparticipant hospitals in non-BPCI markets to replicate methods in formal CMS evaluations (eMethods 2 in Supplement 1). 2, 3, 17 The robustness of these results was evaluated in several ways. The assumption of parallel trends under our f Resides in a zip code area with a median income in the bottom quartile of the national median zip code areas or in a zip code area in which residents with less than a high school education is in the top quartile nationally.
g The score ranges from −20 to 90 with increasing scores highly correlated with increased probability of in-hospital death.
h These values represent the differences in Elixhauser score between the periods.
i Comorbidity score in the top 20% of all patients in the sample.
j Evidence of chronic complications.
k Defined by a list of 15 conditions.
19,20
Research Original Investigation Association Between CMS Bundled Payment Participation and Joint Replacement Volume and Case Mix difference-in-differences method was tested using a generalized linear regression of volume on a BPCI market indicator, time variable, and the interaction, using a Wald test that did not indicate divergent secular trends during the pre-BPCI period (P = .92) (eTable 1 in the Supplement). To evaluate whether volume changes might arise from "pent-up demand" (ie, hospitals delaying procedures until they participated in BPCI), an analogous regression and Wald test was used to conduct a falsification test of whether market volume changed in the year before BPCI. We also examined whether an influx or outflow of volume from beneficiaries crossing over hospital referral regions, or high penetration (top quartile) of ACOs in markets, could explain any volume changes. In addition, volume changes for carotid endarterectomy (not covered under BPCI) and nonelective hip fracture surgery, procedures for which BPCI participation should not be associated with volume changes, were evaluated. The association of BPCI participation and case-mix changes was evaluated using a difference-in-differences method to test for differential changes in the likelihood that patients with certain characteristics would undergo LEJR at participant vs nonparticipant hospitals before and after BPCI was initiated. These analyses used linear regression adjusted for covariates and hospital and quarter fixed effects. As the primary approach, participant hospitals were compared with a 1:1 propensitymatched set of non-BPCI hospitals from non-BPCI markets (eMethods 2 in Supplement 1). In sensitivity analyses, participant hospitals were compared with nonpropensity matched nonparticipant hospitals from non-BPCI markets with and without risk-adjustment.
Hospitals with missing data were excluded from analysis. Statistical tests were 2-tailed and considered significant at α = .05. Robust standard errors were corrected for heteroscedasticity.
22 Analyses were performed using SAS (version 9.4, SAS Institute Inc) and Stata (version 15.1, Stata Corp).
Results
The total number of beneficiaries who underwent LEJR from 2011 through 2015 was 1 717 243 at a BPCI hospital or at a comparison non-BPCI hospital located in a non-BPCI market ( Table 1 ). In the pre-BPCI period, 175 non-BPCI markets represented approximately 13.6 million beneficiaries, 420 518 of whom underwent LEJR (mean LEJR procedures per quarter, 238.3) at 1558 non-BPCI hospitals in these markets ( Before the BPCI initiative launched, the mean age of beneficiaries undergoing LEJR was 75 years; between 64% and 65% were women; and 5% were black. The mean Elixhauser comorbidity index for uncomplicated LEJR was 2 and for complicated, 11.
Market Characteristics
The number of markets with at least 1 BPCI-participant hospital increased to 122, with the mean market share of LEJR procedure paid for through BPCI program increasing to 32% (Figure 1 ; eFigure 1, and eFigure 2A in Supplement 1). Medicare Advantage penetration (23% vs 26%, respectively, P = .93), hospital concentration (HHI of 3856 vs 2629, respectively, P = .98), and skilled nursing facility concentration (HHI of 1860 vs 1168, respectively, P = .13) did not vary across non-BPCI and BPCI markets, whereas ACO penetration was higher in BPCI markets (4% vs 5%, P = .009) ( Table 1 and Table 2 ).
Hospital Characteristics
There were 7 BPCI-participant hospitals at the beginning of the BPCI period (eFigure 2B in Supplement 1) 25 and a total of 1340 non-BPCI hospitals in non-BPCI markets. The number of BPCIparticipant hospitals increased after the program began to a maximum number of 322, although only 293 hospitals participated in late 2015 due to drop out. 25 Seven hundred twentynine non-BPCI hospitals and 21 BPCI-participant hospitals had at least one quarter without data on LEJR episodes and were thus considered to have zero volume for those quarters. The BPCI participant and nonparticipant hospitals in non-BPCI markets varied with respect to a number of characteristics (Table 3) . Compared with non-BPCI hospitals in non-BPCI markets, BPCI-participant hospitals were larger (mean number of beds, 324 vs 213; P < .001) and more likely to be urban (95% vs 72%), not-for-profit (76% vs 65%), and teaching (75% vs 48%) hospitals (P < .001 for all). The BPCIparticipant hospitals had more total (12 939 vs 6796) and Medicare (5912 vs 3209) admissions (P < .001 for both). At baseline, BPCI-participant hospitals were more likely than non-BPCI hospitals to have joint replacement complication (5% vs 2%) and readmission (18% vs 8%) rates higher than national means (P < .001 for both).
Market Volume
There were similar increases in the number of beneficiaries between the before and after periods in both the non-BPCI markets (increase from ≈13.6 to ≈13.8 million beneficiaries) and BPCI markets (increase from ≈18.0 to ≈18.2 million beneficiaries; Table 1 ).
In non-BPCI markets, quarterly mean market volume was 238 for all LEJR episodes in the pre-BPCI period and 252 for episodes in the BPCI period, corresponding to 3.8 and 3.9 episodes per 1000 beneficiaries, respectively (P < .001) ( Table 4 ; and eTable 3 in Supplement 1). Quarterly mean volume for uncomplicated LEJR increased from 229 to 243 episodes, corresponding to 3.6 to 3.8 episodes per 1000 beneficiaries (P < .001), but did not change significantly for complicated LEJR (10 episodes or 1.6 episodes per 1000 beneficiaries in both periods, The method adjusts for patient factors but does not adjust for hospital characteristics.
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Research Original Investigation Association Between CMS Bundled Payment Participation and Joint Replacement Volume and Case Mix P = .87). Similarly, in BPCI markets, quarterly mean market volume increased for all LEJR procedures (407 episodes or 3.6 episodes per 1000 beneficiaries in the pre-BPCI period and 436 episodes or 3.8 episodes per 1000 beneficiaries in the BPCI period, P < .001) and for uncomplicated LEJR (390 episodes or 3.5 episodes per 1000 beneficiaries to 419 episodes or 3.7 episodes per 1000 beneficiaries, respectively, P < .001), but not for complicated LEJR (17 episodes or 1.5 episodes per 1000 beneficiaries in both periods, P = .05).
In unadjusted analysis, the differential change in market volume in BPCI vs non-BPCI markets was 0.01 episodes per 1000 beneficiaries (0.6%, P = .54) for all LEJR episodes, 0.0 episodes per 1000 beneficiaries (0.8%, P = .45) for uncomplicated LEJR, and 0.0 episodes per 1000 beneficiaries (−3.3%, P = .42) for complicated LEJR. In adjusted analysis, BPCI participation was not significantly associated with an increase in market-level LEJR volume (adjusted difference-in-differences estimate, 0.32% increase in LEJR market volume from before BPCI to the BPCI period for BPCI vs non-BPCI markets, 95% CI, −0.06% to 0.69%, P = .10; Table 4 and Figure 2) . Participation was associated with a statistically significant 0.39% differential increase for uncomplicated LEJR (95% CI , 0.01% to 0.77%, P = .04), but not for complicated LEJR (−1.1%; 95% CI, −2.38% to 0.20%, P = .10; eFigure 3 in Supplement 1).
Case mix
Of 322 BPCI hospitals, 265 were propensity matched with 265 non-BPCI hospitals in non-BPCI markets with balanced hospital characteristics across matched hospitals (eTable 4 in Supplement 1). In adjusted analysis, hospital participation was associated with case-mix changes for prior skilled nursing facility use, with these patients less likely to undergo LEJR at participant hospitals vs nonparticipant hospitals (difference-in-difference estimate −0.53%, 95% CI −0.96% to −0.10%, P = .01) (Figure 3 ). There were no significant associations of BPCI participation with 19 other demographic, socioeconomic, clinical, and prior utilization factors.
Sensitivity Analysis
Results from analyzing LEJR volume and market share at the hospital level were qualitatively similar to market-level results (eTable 5 in Supplement 1). Trends in case-mix changes were generally similar between primary and sensitivity analyses (eFigures 4 and 5 in Supplement 1).
Additional Analyses
Differential changes in uncomplicated LEJR volume were not associated with shifting procedures from the year immediately before to the year after BPCI participation was initiated and were consistent with the primary analysis when analyzing markets based on patient residence rather than hospital location (eTable 6 in Supplement 1). Participation was not associated with volume increases for nonelective hip fracture surgery or carotid endarterectomy or when stratifying analyses by ACO penetration (eTables 6 and 7 in Supplement 1).
Discussion
In this study, BPCI participation was not significantly associated with a change in overall volume of LEJR episodes, estimated as a nonsignificant differential increase in episodes of 0.32% (95% CI, −0.06% to 0.69%, P = .10). Participation was not associated with changes in most case-mix factors but was associated with a small, statistically significant reduction of 0.53% in the likelihood of undergoing LEJR among beneficiaries with prior skilled nursing facility use (95% CI, −0.96% to −0.10%, There were 212 922 beneficiaries who underwent lower extremity joint replacement (LEJR) surgery at the 265 matched Bundled Payments for Care Improvement (BPCI) hospitals and 212 951 beneficiaries at the 265 matched non-BPCI hospitals. The association between BPCI participation and the change in probability of a beneficiary with each characteristic receiving LEJR surgery between hospital types and between periods is estimated with a separate difference-in-differences linear probability regression model (ordinary least squares). The estimate for each patient characteristic indicates the difference in the probability comparing the before and after changes at BPCI vs non-BPCI hospitals. The propensity matching model is described in detail in eMethods 2 in the Supplement.
a Race was broken out as black vs others because of existing disparities in access to LEJR among black patients specifically. Other race/ethnicity includes white, Asian, Hispanic, North American Native, and other as defined by Medicare.
b Dual eligible indicates eligibility for both the Medicare and Medicaid programs as an indicator of low socioeconomic status.
c The variables low-median income level zip code and low-education level zip code are binary variables indicating that a beneficiary resides in a zip code with a median income in the bottom quartile of median zip code income nationally or with a proportion of residents with less than a high school education that is in the top quartile among zip codes nationally, respectively.
d See the Methods section for definition of complexity.
e Evidence of chronic complications.
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Association Between CMS Bundled Payment Participation and Joint Replacement Volume and Case Mix P = .01). These findings have 2 important policy implications in light of the forthcoming BPCI-Advanced program. First, to our knowledge, this study provides the first empirical evidence that there were no significant changes in overall LEJR volume under the BPCI initiative. Supported by analyses adjusted for a range of patient, hospital, and market factors, this result is important for mitigating concerns that hospital participation in voluntary bundles may increase the overall number of LEJR procedures paid for by Medicare and decrease or altogether eliminate the program's savings. 7, 8 In particular, this finding suggests that the 3.8% savings per episode observed in prior BPCI evaluations 17 is not reduced through an increase in procedural volume. Furthermore, hospital-level analyses demonstrate that if BPCIparticipant hospitals experienced any volume changes relative to non-BPCI hospitals, they would have more likely reflected shifts between hospitals within markets (ie, an increase in market share for BPCI-participant hospitals) rather than increases in overall market volume. Second, the lack of changes in likelihood of undergoing LEJR at BPCI hospitals along most demographic, socioeconomic, and clinical patient characteristics is reassuring, particularly in light of preexisting disparities in access to and outcomes for LEJR and concerns that hospitals accountable for cost and quality may try to avoid patients with unfavorable risk profiles.
27-30 However, though small, the observed change for patients with prior use of skilled nursing facilities is notable because many hospitals achieved savings by decreasing discharges to institutional postacute care facilities. 5, 17 This finding does raise the possibility that hospitals avoided these patients based on high perceived risk of poor clinical and financial outcomes. Such patient selection may represent a negative unintended consequence of bundled payments and occurs at a relatively notable rate for some patients. For example, the 0.53% (95% CI, −0.96% to −0.10%) reduction in patients with prior skilled nursing facility use undergoing LEJR at BPCI-participant hospitals corresponds to a relative reduction of 8.4%. Conversely, it is not clear that reductions in LEJR for beneficiaries with prior skilled nursing facility use definitively reflects a decrease in patient welfare. For these patients, a lower likelihood of undergoing LEJR under BPCI might reflect clinically appropriate discretion in assessing surgical candidacy (ie, reductions among those for whom LEJR may be inappropriate due to high operative or complication risk). Although this study is unable to distinguish between appropriate and inappropriate patient selection and therefore whether changes were detrimental or beneficial for patients more generally, it is reassuring that patient selection was not observed. 31, 32 Nevertheless, these findings reinforce the need to monitor trends in access and outcomes for vulnerable beneficiaries who may be candidates for LEJR under bundled payments, particularly because of well-known disparities under fee-for-service reimbursement. 28, 30 Given that bundled payments have been associated with improvements in quality and lower cost of LEJR, further research is needed to evaluate whether vulnerable beneficiaries and their communities can access and experience such benefits.
Limitations
This study has several limitations. First, results were limited by the inability to examine long-term effects as well as potential confounding from omitted variables with coincident trends, and downward bias from low market-level BPCI participation that may have led to inadequate power to detect a statistically significant difference between the 3.8% and 4.4% changes in volume in non-BPCI and BPCI markets, respectively. However, the chance of spurious findings was mitigated by consistency of results across robustness checks (eg, falsification tests, tests of alternate explanations, and hospital-level analyses). Second, strong secular trends could have been driven by the profitability of LEJR, dampening the ability to observe volume increases under BPCI. However, the effect of BPCI policy would have been analogously dampened, and methods that account for secular trends were used. Third, analyses may not generalize to other episodes, particularly for medical conditions. Fourth, while this study focuses on BPCI Model 2, it is the largest model by enrollment and is the basis for BPCI-Advanced. 
Conclusions
In this observational study of Medicare beneficiaries who underwent lower extremity joint replacement, hospital participation in Bundled Payments for Care Improvement was not associated with changes in market-level lower extremity joint replacement volume and largely was not associated with changes in hospital case mix. These findings may provide reassurance regarding 2 potential unintended effects associated with bundled payments for lower extremity joint replacement. We used a continuous quarterly measure of the LEJR market share for BPCI markets (n=131). We first measured LEJR market shares at each hospital in the pre-BPCI period (2011 Quarter 1 to 2013 Quarter 3). Market shares were measured in the pre-BPCI period to avoid the circularity that would result from measuring LEJR market volume as both a dependent variable and component of the independent variable. Second, in each post-BPCI quarter, we summed the pre-BPCI LEJR market shares for hospitals that were participating in BPCI in that quarter in that market -and assigned this market-level value as the quarterly exposure to BPCI in BPCI markets (Figure 1 ). This market-quarter value was updated in each quarter so that as more hospitals joined BPCI within a market, the value of market-level BPCI participation grew. In this figure, we plot the mean of the exposure variable based on pre-BPCI LEJR market share (Pre-BPCI) and the mean of the observed LEJR market share of BPCI participating hospitals at the market level by quarter. This figure demonstrates that the exposure variable, which was used to avoid circularity in the regression (i.e., LEJR market volume on both sides of the regression equation), tracks very closely with the observed LEJR market share of BPCI participating hospitals. We then used these scenarios to estimate changes in LEJR volume based on actual market share of BPCI participating hospitals and plotted them in Figure 2 (all LEJR volume) and eFigure 3 (uncomplicated LEJR).
At the average market exposure of 14%, BPCI markets would have experienced a differential 0.40% volume increase (i.e., 0.06 additional procedures per BPCI market per quarter) for uncomplicated LEJR in 2014-2015, though for all LEJR (0.32%) and complicated LEJR (-1.2%) the changes in volume were not statistically significant.
eMethods 2. Propensity score matching of BPCI hospitals to non-BPCI hospitals in non-BPCI markets
To decrease differences between BPCI participant hospitals and Non-BPCI hospitals, we used propensity score matching on a variables drawn from Medicare claims and AHA Annual Survey data (see eTable 4 below for all the variables). Our propensity model used logistic regression with a binary dependent variable of participation in BPCI during any quarter in the BPCI period for the LEJR episode and independent variables listed in eTable 4. We further limited Non-BPCI hospitals to those located in markets without any BPCI participation (Non-BPCI markets) because Non-BPCI hospitals in BPCI markets may still be affected by the policy because of shifting of volume and case-mix between Non-BPCI and BPCI hospitals. Using a minimum of a 2 digit propensity score match, we were able to match 265 out of 322 BPCI hospitals with Non-BPCI hospitals in Non-BPCI markets in a 1:1 match. 
Patient mix
Medicare utilization ratio, mean ( a From the AHA Annual Survey, major teaching hospitals are those that are members of the Council of Teaching Hospitals (COTH), minor teaching hospitals are non-COTH members that had a medical school affiliation reported to the American Medical Association, and nonteaching hospitals are all other institutions. b Hospital Margin is calculated as the difference between total net revenue and total expenses divided by total net revenue.
c Safety-net hospitals were defined as being in the top quartile of disproportionate share (DSH) payment percentage, using the FY2017 CMS IMPACT file.
